Bristol-Myers Squibb R&D decreased by 2.0% to $2.53B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.5%, from $2.37B to $2.53B. Over 3 years (FY 2021 to FY 2024), R&D shows relatively stable performance with a -0.6% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
High spending signals a commitment to future growth and innovation, though it reduces current period earnings.
Detailed definition
Expenses related to the development of new products, services, and technologies, as well as the improvement of existing...
Peer comparison
Tech leaders often spend a significant percentage of revenue on R&D to prevent disruption by competitors.
Metric ID:
is_research_and_developmentHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.27B | $3.25B | $2.61B | $2.26B | $2.32B | $2.42B | $2.51B | $2.32B | $2.26B | $2.24B | $2.48B | $2.70B | $2.90B | $2.37B | $3.19B | $2.26B | $2.58B | $2.53B |
| QoQ Change | — | -0.6% | -19.8% | -13.3% | +2.7% | +4.2% | +3.8% | -7.5% | -2.7% | -0.7% | +10.5% | +8.8% | +7.6% | -18.1% | +34.4% | -29.3% | +14.3% | -2.0% |
| YoY Change | — | — | — | — | -29.0% | -25.6% | -3.7% | +2.7% | -2.7% | -7.3% | -1.3% | +16.1% | +28.4% | +5.9% | +28.8% | -16.3% | -11.0% | +6.5% |
Range$2.24B – $3.27B
CAGR-5.9%
Avg YoY Growth-0.6%
Median YoY Growth-2.0%
R&D at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's r&d?
- Bristol-Myers Squibb (BMY) reported r&d of $2.53B in Q3 2025.
- How has Bristol-Myers Squibb's r&d changed year-over-year?
- Bristol-Myers Squibb's r&d increased by 6.5% year-over-year, from $2.37B to $2.53B.
- What is the long-term trend for Bristol-Myers Squibb's r&d?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's r&d has grown at a -0.6% compound annual growth rate (CAGR), from $11.35B to $11.16B.
- What does r&d mean?
- The money spent on creating new technology and improving existing products.